XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

SPECIAL (GAINS) AND CHARGES | 6 Months Ended
--- | ---
Jun. 30, 2024
SPECIAL (GAINS) AND CHARGES |
SPECIAL (GAINS) AND CHARGES | 3. SPECIAL (GAINS) AND CHARGES ​ Special (gains) and charges reported on the Consolidated Statements of Income include the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Second Quarter Ended | ​ | Six Months Ended | ​
​ | ​ | June 30 | ​ | June 30 | ​
(millions) |  | 2024 | ​ | 2023 |  | 2024 | ​ | 2023 | ​
Cost of sales | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring activities | ​ | ​ | $0.7 | ​ | ​ | ​ | $8.1 | ​ | ​ | $2.3 | ​ | ​ |  | $11.3 | ​
Cost of sales subtotal | ​ | ​ | 0.7 | ​ | ​ | ​ | 8.1 | ​ | ​ | 2.3 | ​ | ​ |  | 11.3 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Special (gains) and charges | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring activities | ​ | ​ | 6.9 | ​ | ​ | ​ | 13.7 | ​ | ​ | 25.0 | ​ | ​ |  | 26.3 | ​
Sale of global surgical solutions business | ​ | ​ | 7.3 | ​ | ​ | ​ | - | ​ | ​ | 13.3 | ​ | ​ | ​ | - | ​
Acquisition and integration activities | ​ | ​ | 2.3 | ​ | ​ | ​ | 3.5 | ​ | ​ | 4.8 | ​ | ​ | ​ | 8.5 | ​
Other | ​ | ​ | (4.3) | ​ | ​ | ​ | 3.8 | ​ | ​ | (2.7) | ​ | ​ |  | 10.7 | ​
Special (gains) and charges subtotal | ​ | ​ | 12.2 | ​ | ​ | ​ | 21.0 | ​ | ​ | 40.4 | ​ | ​ |  | 45.5 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total special (gains) and charges | ​ | ​ | $12.9 | ​ | ​ | ​ | $29.1 | ​ | ​ | $42.7 | ​ | ​ | ​ | $56.8 | ​
​ For segment reporting purposes, special (gains) and charges are not allocated to reportable segments, which is consistent with the Company’s internal management reporting. ​ Restructuring activities ​ Restructuring activities are primarily related to the Combined Program which is described below. These activities have been included as a component of cost of sales and special (gains) and charges on the Consolidated Statements of Income. Restructuring liabilities have been classified as a component of other current and other noncurrent liabilities on the Consolidated Balance Sheets. ​ Combined Program ​ In November 2022 the Company approved a Europe cost savings program. In February 2023, the Company expanded its previously announced Europe cost savings program to focus on its Institutional and Healthcare businesses in other regions. In connection with the expanded program (“the Combined Program”), the Company expects to incur total pre-tax charges of $195 million ($150 million after tax). The Company expects that these restructuring charges will be substantially completed by the end of 2024. Program actions include headcount reductions from terminations, not filling certain open positions, and facility closures. The Combined Program charges are expected to be primarily cash expenditures related to severance and asset disposals. ​ In anticipation of this Combined Program, a limited number of actions were taken in the fourth quarter of 2022. As a result, the Company reclassified $19.3 million ($14.5 million after tax) from other restructuring to the Combined Program in the first quarter of 2023. During the second quarter of 2024 and 2023, the Company recorded restructuring charges of $2.3 million ($1.4 million after tax) and $19.7 million ($16.2 million after tax), respectively, and during the first six months of 2024 and 2023 $22.0 million ($17.2 million after tax) and $33.1 million ($26.4 million after tax), respectively, primarily related to severance and professional services. The Company has recorded $180.9 million ($150.1 million after tax) of cumulative charges under the Combined Plan. ​ The Company reclassified $5.3 million ($4.0 million after tax) from the combined restructuring program to other restructuring in the second quarter of 2024. ​ The net liability related to the Combined Program was $32.2 million and $43.1 million as of June 30, 2024 and December 31, 2023, respectively. The remaining liability is expected to be paid over a period of a few months to several quarters and will continue to be funded from operating activities. ​ Restructuring activity related to the Combined Program since inception of the underlying actions includes the following items: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  |  | ​ | ​ |  | ​ | ​ |  | ​
​ | ​ | Employee | ​ | Asset | ​ | ​ | ​ | ​ | ​ | ​
(millions) |  | Costs |  | Disposals |  | Other |  | Total
2022-2023 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense and accrual | ​ | ​ | $114.2 | ​ | ​ | ​ | $14.0 | ​ | ​ | ​ | $16.7 | ​ | ​ | ​ | $144.9 | ​
Net cash payments | ​ | ​ | (90.4) | ​ | ​ | ​ | - | ​ | ​ | ​ | (16.7) | ​ | ​ | ​ | (107.1) | ​
Non-cash charges | ​ | ​ | - | ​ | ​ | ​ | (14.0) | ​ | ​ | ​ | - | ​ | ​ | ​ | (14.0) | ​
Reclassification | ​ |  | 19.3 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ |  | 19.3 | ​
Net restructuring liability, December 31, 2023 | ​ | ​ | 43.1 | ​ | ​ | ​ | - | ​ | ​ | ​ | - | ​ | ​ | ​ | 43.1 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2024 Activity | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Recorded expense and accrual | ​ | ​ | 3.8 | ​ | ​ | ​ | 0.7 | ​ | ​ | ​ | 17.5 | ​ | ​ | ​ | 22.0 | ​
Net cash payments | ​ | ​ | (18.8) | ​ | ​ | ​ | - | ​ | ​ | ​ | (8.1) | ​ | ​ | ​ | (26.9) | ​
Non-cash charges | ​ | ​ | - | ​ | ​ | ​ | (0.7) | ​ | ​ | ​ | - | ​ | ​ | ​ | (0.7) | ​
Reclassification | ​ |  | - | ​ | ​ | ​ | - | ​ | ​ | ​ | (5.3) | ​ | ​ | ​ | (5.3) | ​
Net restructuring liability, June 30, 2024 | ​ | ​ | $28.1 | ​ | ​ | ​ | $- | ​ | ​ | ​ | $4.1 | ​ | ​ | ​ | $32.2 | ​
​ Other Restructuring Activities ​ During 2024, the Company incurred restructuring charges of $10.6 million ($8.0 million after tax) related to an immaterial restructuring plan approved in the second quarter. ​ The restructuring liability balance for all other restructuring plans excluding the Combined Program was $9.0 million as of the end of the second quarter. ​ One Ecolab ​ On July 30, 2024, the Company announced the One Ecolab initiative, which will enhance its growth and margin expansion journey. As a program within this initiative, the Company also announced that it commenced a restructuring plan to leverage its digital technologies to realign the functional work done in many countries into global centers of excellence. The Company anticipates restructuring costs of $175 million ($136 million after tax) and special charges of $50 million ($39 million after tax) by the end of 2027. The Company anticipates that the restructuring costs will primarily be cash expenditures for severance costs relating to team reorganization. ​ Sale of global surgical solutions business On April 27, 2024, the Company reached a definitive agreement to sell its global surgical solutions business. The Company recorded charges of $7.3 million ($3.1 million gain after tax) and $13.3 million ($1.4 million after tax) in the second quarter and first six months of 2024, respectively, which are primarily related to professional fees to support the sale. The tax benefit is driven by a reduction to the Company’s valuation allowance on capital loss carryforwards. ​ Acquisition and integration related costs ​ Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income include $2.3 million ($1.7 million after tax) and $3.5 million ($2.7 million after tax) in the second quarter of 2024 and 2023, respectively. Acquisition and integration related costs reported in special (gains) and charges on the Consolidated Statements of Income include $4.8 million ($3.6 million after tax) and $8.5 million ($6.4 million after tax) in the first six months of 2024 and 2023, respectively. ​ Further information related to the Company’s acquisitions is included in Note 4. ​ ​ Other operating activities ​ Other special (gains) and charges of ($4.3 million) ($3.1 million gain after tax) and $3.8 million ($2.8 million after tax) recorded in the second quarter of 2024 and 2023, respectively, and ($2.7 million) ($2.2 million gain after tax) and $10.7 million ($8.2 million after tax) recorded in the first six months of 2024 and 2023, respectively, related primarily to recoveries of COVID era credits, professional fees and certain legal charges, which are recorded in special (gains) and charges on the Consolidated Statements of Income.

X
- References No definition available. + Details
Name: | ecl_SpecialGainsAndChargesDisclosureAbstract
Namespace Prefix: | ecl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount of other nonrecurring expenses, not previously categorized, that are infrequent in occurrence or unusual in nature. + References No definition available. + Details
Name: | ecl_SpecialGainsAndChargesTextBlock
Namespace Prefix: | ecl_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration